Winrevair Approved for Pulmonary Arterial Hypertension
Winrevair is a first-in-class recombinant activin receptor type IIA-Fc fusion protein designed to bind to activin A and other TGF-β superfamily ligands.
Winrevair is a first-in-class recombinant activin receptor type IIA-Fc fusion protein designed to bind to activin A and other TGF-β superfamily ligands.
This Viewpoint examines the significant gap in knowledge regarding the effects of cannabis use on perinatal health outcomes.
Removing the “reasonable punishment” defence and prohibiting corporal punishment of children can help to reduce family violence, says Andrew Rowland In England and Northern Ireland,…
Doctor activists are in the news. Sarah Benn, a former GP from Birmingham, has had her medical licence suspended for five months after being arrested…
Passing infection or something far more serious?
Canadians support it, public health demands it, now policy makers must deliver it Canada’s universal healthcare system, often referred to as Medicare, provides universal, public…
A panel of experts provide an overview of gene therapy, review recently approved gene therapies for rare diseases such as hemophilia, spinal muscular atrophy, and…
You know losing that extra weight would be good for your health. Your health care team talked with you about […]
Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.
Objective To evaluate the implementation of an antimicrobial stewardship programme-led inpatient beta-lactam allergy de-labelling programme using a direct oral provocation test (OPT). Design One-year quality…
Professional medical textbooks for the medical, dental, veterinary, nursing, and other health professional fields. Free UPS Shipping on all orders.